Over the last years, it was hypothesized that the higher rate of TP53 mutations in t-AML was directly associated with the cytotoxic effect of chemotherapy and radiation on hematopoietic stem/progenitor cell (HSPC) DNA. The gene discussed is TP53; the disease is acute myeloid leukemia.